Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort
暂无分享,去创建一个
Andrew J. Saykin | Jingwen Yan | Li Shen | Hong Liang | Lei Wang | Feng Chen | Weixing Feng | Sungeun Kim | Jin Li | A. Saykin | Sungeun Kim | F. Chen | Jingwen Yan | Weixing Feng | Li Shen | Jin Li | Hong Liang | Qiushi Zhang | Lei Wang | Qiushi Zhang | L. Shen
[1] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[2] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[3] D. G. Clark,et al. Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.
[4] Masanori Kato,et al. Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease , 1993, Neuroscience Letters.
[5] J. Hardy,et al. A nonsense mutation in PRNP associated with clinical Alzheimer's disease , 2014, Neurobiology of Aging.
[6] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[7] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[8] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[9] O. Combarros,et al. Epistasis between intracellular cholesterol trafficking-related genes (NPC1 and ABCA1) and Alzheimer's disease risk. , 2010, Journal of Alzheimer's disease : JAD.
[10] O. Combarros,et al. Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK‐3β) and Alzheimer’s disease risk , 2009, Acta neurologica Scandinavica.
[11] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[12] D. G. Clark,et al. Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease , 2011 .
[13] Michael W. Weiner,et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study , 2013, Molecular Psychiatry.
[14] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[15] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[16] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[17] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[18] D. Price,et al. Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.
[19] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[20] Paul M. Thompson,et al. Transcriptomics of cortical gray matter thickness decline during normal aging , 2013, NeuroImage.
[21] Pinchas Cohen,et al. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] Andrew J. Saykin,et al. Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease , 2009, PloS one.
[23] Jason H. Moore,et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers , 2013, Brain Imaging and Behavior.
[24] Tricia A. Thornton-Wells,et al. Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography , 2013, Human Genetics.
[25] S. Potkin,et al. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: Methodological considerations , 2009, Cognitive neuropsychiatry.
[26] Michael Weiner,et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.
[27] R. Petersen,et al. Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease , 2010, Human Genetics.
[28] O. Combarros,et al. Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk , 2009, Brain Research.
[29] Jason H. Moore,et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.
[30] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[31] Tim Becker,et al. INTERSNP: genome-wide interaction analysis guided by a priori information , 2009, Bioinform..
[32] Tricia A. Thornton-Wells,et al. Genetic Interactions Associated with 12-month Atrophy in Hippocampus and Entorhinal Cortex in Alzheimer's Disease Neuroimaging Initiative , for the Alzheimer's Disease Neuroimaging Initiative , 2022 .
[33] J. Trojanowski,et al. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.
[34] Nick C Fox,et al. Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .
[35] Nick C Fox,et al. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .
[36] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[37] Mark E. Schmidt,et al. The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[38] Nick C Fox,et al. Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .
[39] T. Yen,et al. Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [18F]AV-45 Positron Emission Tomography in Chinese Population , 2013, PloS one.
[40] R. Tanzi,et al. The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.
[41] S. Potkin,et al. Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.
[42] P. Donnelly,et al. Inference of population structure using multilocus genotype data. , 2000, Genetics.
[43] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[44] V Shane Pankratz,et al. Replication of BIN1 association with Alzheimer's disease and evaluation of genetic interactions. , 2011, Journal of Alzheimer's disease : JAD.
[45] Simon Lovestone,et al. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS) , 2012, Neurobiology of Aging.
[46] W. Marsden. I and J , 2012 .
[47] Michelle K. Lupton,et al. Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease , 2014, Neurobiology of Aging.
[48] Nick C Fox,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.
[49] M. Nalls,et al. Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype , 2013, Biological Psychiatry.